Related Experiment Video
Updated: Dec 25, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili1, Marie-France Langelier2, Uday Kiran Velagapudi3
1Department of Biochemistry and Biophysics, Penn Center for Genome Integrity, Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
The success of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors (PARPi) to treat cancer relates to their ability to trap PARP-1 at the site of a DNA break. Although different forms of PARPi all target the catalytic center of the enzyme, they have variable abilities to trap PARP-1. We found that several structurally distinct PARPi drive PARP-1 allostery to promote release from a DNA break. Other inhibitors drive allostery to retain PARP-1 on a DNA break. Further, we generated a new PARPi compound, converting an allosteric pro-release compound to a pro-retention compound and increasing its ability to kill cancer cells. These developments are pertinent to clinical applications where PARP-1 trapping is either desirable or undesirable.
Insights
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors trap PARP-1 at DNA breaks. Researchers developed a new inhibitor that retains PARP-1, enhancing cancer cell killing and offering new clinical options.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors (PARPi) are crucial in cancer treatment by trapping PARP-1 at DNA breaks.
- Existing PARPi exhibit variable trapping efficiencies despite targeting the enzyme's catalytic center.
Purpose of the Study:
- To investigate the allosteric mechanisms by which different PARPi influence PARP-1 retention or release from DNA breaks.
- To engineer a novel PARPi with enhanced cancer cell-killing capabilities by modulating PARP-1 allostery.
Main Methods:
- Structural analysis of diverse PARPi interactions with PARP-1.
- Allosteric modulation studies to assess PARP-1 release and retention dynamics.
- Development and evaluation of a novel PARPi compound.
Main Results:
- Structurally distinct PARPi were found to induce allosteric changes promoting either PARP-1 release or retention at DNA breaks.
- A newly synthesized PARPi converted an allosteric pro-release compound into a pro-retention agent.
- The engineered pro-retention PARPi demonstrated increased efficacy in killing cancer cells.
Conclusions:
- PARP-1 allostery is a critical determinant of inhibitor efficacy and DNA break trapping.
- Targeting PARP-1 allostery offers a promising strategy for developing more effective cancer therapeutics.
- The ability to control PARP-1 retention versus release has significant implications for clinical applications of PARPi.
More Related Videos
Related Concept Videos
Long-patch Base Excision Repair
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Base Excision Repair
The first step of...
Base Excision Repair

